- Home
- CNO vs KNSA Comparison
CNO vs KNSA Comparison
Compare CNO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNO | KNSA |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNO | KNSA |
|---|---|---|
| Price | $39.89 | $46.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $46.25 | ★ $55.29 |
| AVG Volume (30 Days) | 555.5K | ★ 580.2K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $38.01 |
| Revenue Next Year | $3.32 | $17.42 |
| P/E Ratio | ★ $18.71 | $62.41 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $35.24 | $18.26 |
| 52 Week High | $44.86 | $49.12 |
Technical Indicators
Market Signals| Indicator | CNO | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 54.56 |
| Support Level | $38.86 | $40.47 |
| Resistance Level | $40.42 | $46.48 |
| Average True Range (ATR) | 1.15 | 2.11 |
| MACD | -0.27 | 0.02 |
| Stochastic Oscillator | 9.87 | 63.12 |
Price Performance
Historical ComparisonAbout CNO CNO Financial Group Inc.
CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.